Skip to main content
. 2021 May 18;12:2928. doi: 10.1038/s41467-021-23250-5

Fig. 3. The fluorescently measured data in homogenous solution to demonstrate the FBS stability of siRNA/Ap-CS formulation, where siRNA was FAM-modified siLuc.

Fig. 3

a Schematic illustration of the method for evaluation of the AuNP-confined siRNA stability. b Quantitative evaluation of the retention (%) of surface-confined siRNAs after exposure of four different siRNA-encapsulated formulations (i–iv) to FBS, where the retention efficiency of nontreated formulation corresponding to each group is defined as 100%. Samples a-e represent the solutions of Nanoparticle-i + PBS, Nanoparticle-i + 10% FBS, Nanoparticle-ii +10% FBS, Nanoparticle-iii +10% FBS, and Nanoparticle-iv +10% FBS, respectively. Nanoparticle-i is the siRNA/Ap-CS with the compact protective coating assembled from lying/cross-linking YTDB-a; Nanoparticle-ii and Nanoparticle-iii are the same as Nanoparticle-i but substituting YTDB-a with lying YTDB-b and standing YTDB-c, respectively. Nanoparticle-iv indicates siRNA/ADC-AuNP without the protective coating. More information can be seen in the section of “Retention (%) assay of siRNA on AuNPs after treatment with 10% FBS” in “Methods”. The error bar represents the standard deviation (SD). The measured data are expressed as the means ± SD (n = 3).